Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
Table 3
EORTC QLQ-C30 functional and symptom scales at and compared to the pooled European normative data [28].
EORTC QLQ-C30
Mean (SD) value
Range
Mean (SD) value
Range
European mean (SD)
Function scales
Physical
84.3 (15.3)
[47-100]
80.9 (16.3) p = 0.33
[53-100]
85.1 (18.9)
Role
85.3 (21.2)
[33-100]
81.1 (18.7)
[50-100]
84.3 (24.6)
Emotional
79.9 (29.0)
[0-100]
80.0 (17.5)
[50-100]
74.2 (24.7)
Cognitive
72.6 (27.6)
[0-100]
64.4 (25.9)
[17-100]
84.8 (21.3)
Social
85.3 (21.2)
[33-100]
77.8 (25.7)
[33-100]
86.2 (24.1)
Global QOL
76.0 (17.4)
[50-100]
72.2 (22.9)
[42-100]
66.1 (21.7)
Symptom scales/items
Fatigue
27.5 (25.8)
[0-78]
21.5 (20.4)
[0-67]
29.5 (25.5)
Nausea/vomiting
2.0 (5.5)
[0-17]
5.6 (15.0)
[0-50]
5.9 (16.0)
Pain
12.7 (16.2)
[0-33]
18.9 (23.5)
[0-67]
23.5 (27.1)
Dyspnea
13.7 (29.0)
[0-100]
15.6 (24.8)
[0-67]
15.9 (24.6)
Insomnia
11.8 (16.4)
[0-33]
13.3 (21.1)
[0-67]
26.6 (30.3)
Appetite loss
7.8 (18.7)
[0-67]
15.6 (33.0)
[0-100]
10.0 (21.6)
Constipation
5.9 (17.6)
[0-67]
9.0 (23.4)
[0-67]
12.5 (23.3)
Diarrhea
11.8 (20.2)
[0-67]
6.7 (13.8)
[0-33]
9.5 (20.9)
Financial difficulties
13.7 (33.5)
[0-100]
13.4 (24.7)
[0-67]
10.6 (23.6)
Bilateral one sample -tests have been conducted to compare the means with the normative data of the pooled European normative data. (0.2 = small effect, 0.5 = medium effect, and 0.8 = large effect). Functional scales: a lower score compared to the European mean indicates a worse functioning. Symptom scales: a higher score compared to the European mean indicates more symptoms.
